MY PICK IS ELN

[tokyojoeskid]

on board

since 20.55
nice pick

[mjmilam]

I am with you, King. Just doubled my shares at 20+.

Melody

[kingofthehill]

great day closed at the high of $22.00 ...

[kingofthehill]

Elan is 50-50 partner on all sales of Antegren with Biogen

Biogen is nearly $60.00 per share
Elan is $22.00 per share
there is more upside to Elan
FRIDAY, APRIL 16, 2004 1:17 p.m. EDT

ELECTRONIC Q&A |
Price's Puglia Likes Cash-Rich Big Caps

By JOHN KIMELMAN

Correction:

LARRY PUGLIA, the manager of T. Rowe Price Blue Chip Growth, beats the large-cap fund pack, whether you're measuring his performance by before- or after-tax returns. His focus on quality companies that generate lots of free cash flow has led to pre-tax returns that best the Standard & Poor's 500 index this year, and over the past three and five years. UnitedHealth Group and American International Group are among two of Puglia's strongest performers this year.
Puglia also scores well after the taxman takes his cut. Because the fund manager holds on to stocks for longer than the average large-cap fund manager -- he has held Citigroup, his largest position, since the fund's launch in 1993--the fund is among the most tax-efficient among the large stock offerings.
So far this year, Puglia's no-load fund, which has $7.5 billion in assets, is up 3.7%, beating the S&P 500 by almost a full percentage point. Barron's Online interviewed him by phone recently about some of his current favorites.

Barron's Online: What stock is your favorite pick, based on recent purchases?
Puglia: My largest new position is Biogen Idec, and that is the only one that I have been adding in the biotech space. This is a name that we bought from scratch recently. The driving force behind the purchase is Antegren, a drug for multiple sclerosis.
There is significant evidence that it not only lessens the severity of the disease and causes less frequent relapse of the disease. But there is underlying clinical evidence that shows that it actually reduces damage or lesions in the brain that are thought to be associated with multiple sclerosis Well, they are just getting approval for that product right now, so it hasn't been marketed yet. It is the kind of product that we really think could drive growth for a three- to five-year period,

[stocks54]

ELN

kingofthehill,

I have been following (on & off) your post regarding Elan. I waited so long to get in... Today I got in...I hope it still has some run left....

Thank for nice pick....

[kingofthehill]

plenty of time just dont let them shake you out with a stop loss order, this stock swings back and forth,

Elan will present at a Morgan Stanley conference May 5th ...these road shows have produced nice moves

I just bought June $30 strike price contract!

good luck

[mjmilam]

Hi King,

What is a June $30 strike price contract and where does one get them? I'm still new at this.

Thanks,
Melody

[kingofthehill]

im talking about option in Elan stock OPTIONS can be very rewarding and or dangerous investment...

so if your new just buy the stock . options are a real gamble

[kingofthehill]

Elan closed today at $23.53!

expect Antegren's launch to expand multiple sclerosis market, as market expansion has
happened following the launch of each new therapy. They are particularly interested in
viewing the Antegren and Avonex combination data given their leadership over Avonex with
Rebif. It appears they are interested in doing trials with Rebif and Antegren in combination if
the combination therapy data shows some synergistic benefit.
The management believe that if substitution does occur within the multiple sclerosis market
following Antegren's approval then it will be the weakest product which will be targeted (they
believe that Copaxone, which has 30% market share in the US, is the weakest target as its
the only non beta-interferon therapy).
Serono's Rebif continues to be the fastest growing therapy in multiple sclerosis and the
company are targeting the product having a market leadership position in both the US and
Europe by the time of Antegren's launch.
Our view on the likely use of single or combination (Antegren & Avonex) therapy is that the
combination therapy will have to show a significant improvement over Antegren alone to
gain meaningful use. Assuming the combination therapy is not significantly more effective
than Antegren alone we believe that the most likely marketing approach for Antegren is to
market the monotherapy aggressively. If efficacy is comparable between the single and
combination therapy treatments the significantly higher cost and poor side-effect profile of
the combination product is likely to limit its use.
David Marshall +353 1 611 5925 [email protected]
Orla Hartford +353 1 611 5844 [email protected]
(EUR) 12/02 12/03 12/04e
Sales (m) 10,517 10,774 11,382
EBITDA (m) 1,487 1,475 1,556
EBITDA margin 14.1% 13.7% 13.7%
Net Profit rep.(m) 623 641 680
EPS (adj.) 1.33 1.36 1.47
Debt/Equity 0.3 0.4 0.3
EV/EBITDA 6.8 6.5 6.9
P/E (adj.) 12.4 10.6 12.1
P/BV 1.6 1.4 1.5
Div idend y ield 1.6 2.0 1.7
Market cap (EURm) 9,379 Free float 99.0%
(USD) 12/02 12/03 12/04e
Sales (m) 1,133 746 494
EBITDA (m) 216 (101) (170)
EBITDA margin 19.1% nm nm
Net Profit rep.(m) (2,391) (560) (359)
EPS (adj.) (0.49) (0.95) (0.84)
Debt/Equity 0.6 0.9 0.8
EV/EBITDA 17.3 nm nm
P/E (adj.) nm nm nm
P/BV 1.6 1.3 11.1
Div idend y ield 0.0 0.0 0.0
Market cap (USDm) 8,937 Free float 97.0%

[kingofthehill]

Elan: In Search of a Blockbuster

http://www.kiplinger.com/columns/picks/archive/2004/pick0422.htm

PICK OF THE DAY


Elan: In Search of a Blockbuster

The key to investing in biotechnology is to understand a company's pipeline of potential products. Erin Xie and Ajay Mehra, co-managers of State Street Research Health Sciences fund (SHSAX) scan medical research and attend conferences to get the skinny on promising new drugs.

One of the team's favorite companies is Irish biotechnology firm Elan (ELN). It has a 50% interest in a possible blockbuster called Antegren, a drug designed to treat multiple sclerosis.

In 2002, Elan's shares fell below $2 in the aftermath of an accounting scandal. They have since rebounded to $23. New management appears to be untainted and, says Xie, has made the company's finances "more transparent" -- meaning they're easier to interpret and more trustworthy.

Elan is losing money, but Xie thinks the company could earn as much as $1.20 per share in a couple of years. Four out of five analysts that closely cover the stock rate it a "buy."

--Jeffrey Kosnett

[kingofthehill]

Biotech is on a tear!

DNA
ELN
BIIB

THATS ALL YOU GOTTA KNOW..PLENTY OF ROOM IN EACH

..but none will rival the move up ELN this summer

[carribean_mike]

King, Do you think that Biotech can run couter to the NASDAQ? The NASDAQ is acting like it wants to go lower.

[kingofthehill]

these 3 stock are special

DNA - its just a winner,

ELN&BIIB have in their hands a possible multi billion dollar drug

as soon as they proved they can deliver approval the stock will sky rocket

even the announcement that the paper work is filed an fast tracked by the FDA will give a punch to both

90% of my $$ is in ELAN, without any fear the CEO of Elan is a winner

I hit very nicely on OSIP options, and Elan will be even bigger

nothing is hotter than Biotech right now

[Michaelk005]

Nothing is hotter than this stock right now, I see easy $30 by end of may..
Quote me on that......

[tscanlon]

While I wish I picked some up back when king first mentioned ELN, I'm looking to pick some up in the near term anyone have any insight to ELN in the short term.

T